Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rituximab Therapy in Refractory Adult and Juvenile Idiopathic Inflammatory Myopathy (IIM)

Next Previous
Trial Profile

Rituximab Therapy in Refractory Adult and Juvenile Idiopathic Inflammatory Myopathy (IIM)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary)
  • Indications Dermatomyositis; Polymyositis
  • Focus Biomarker; Therapeutic Use
  • Acronyms RIM

    • Most Recent Events

    • 09 Nov 2021 Results (n=194) assessing the effect of rituximab on IgG levels of DM/PM/JDM patients and the association of IgG levels with infections retrospectively using the Rituximab in Myositis (RIM) study data, presented at the ACR Convergence 2021.
    • 21 Oct 2014 New source identified and integrated (ClinicalTrials.gov record: NCT00106184)
    • 21 Oct 2014 New source identified and integrated (ClinicalTrials.gov record: NCT00106184)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top